Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition


Por: De Pourcq, JT, Riera, A, Gras, L, Garin, N, Busquets, MA, Cardenete, J, Cardona, D, Riera, P

Publicada: 1 jul 2024
Resumen:
Ceftolozane-tazobactam (CT) is used for the treatment of complicated infections and for multidrug-resistant strains of Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing enterobacteria. In certain cases, simultaneous administration of CT and parenteral nutrition (PN) may be required, but compatibility of Y-site co-administration is unknown. The aim of this study was to analyse the physicochemical compatibility of CT Y-site administered with PN. We evaluated a protocolized PN approach for critical patients in our center. We studied both bolus infusion (2 g ceftolozane/1 g tazobactam in 1 h) and continuous infusion (CI) (6 g ceftolozane/3 g tazobactam) strategies. Samples were visually observed against light, microscopically inspected, and pH was analysed using a pH meter. The mean lipid droplet diameter (MDD) was determined via dynamic light scattering. CT concentration was quantified using HPLC-HRMS. No alterations were observed through visual or microscopic inspection. Changes in pH were <= 0.2, and changes in osmolarity were less than 5%. MDD remained below 500 nm (284.5 +/- 2.1 for bolus CT and 286.8 +/- 7.5 for CI CT). CT concentrations at t = 0 h and t = 24 h remained within prespecified parameters in both infusion strategies. CT is physiochemically compatible with PN during simulated Y-site administration at the tested concentration and infusion rates.

Filiaciones:
De Pourcq, JT:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Dept Med, Barcelona 08025, Spain

 Inst Recerca St Pau IR SANT PAU, Barcelona 08041, Spain

Riera, A:
 Hosp St Pau & Santa Tecla, Dept Pharm, Tarragona 43003, Spain

Gras, L:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

 Inst Recerca St Pau IR SANT PAU, Barcelona 08041, Spain

Garin, N:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

 Univ Ramon Llull, Sch Hlth Sci Blanquerna, Barcelona 08025, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid 28007, Spain

Busquets, MA:
 Univ Barcelona, Inst Nanosci & Nanotechnol IN2UB, Barcelona 08028, Spain

 Univ Barcelona, Fac Pharm & Food Sci, Dept Pharm & Pharmaceut Technol & Phys Chem, Barcelona 08028, Spain

Cardenete, J:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

 Inst Recerca St Pau IR SANT PAU, Barcelona 08041, Spain

Cardona, D:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

Riera, P:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Pharm, Barcelona 08025, Spain

 Inst Recerca St Pau IR SANT PAU, Barcelona 08041, Spain

 Inst Salud Carlos III, CIBER Enfermedades Raras CIBERER, Madrid 28029, Spain
ISSN: 14248247
Editorial
MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 17 Número: 7
Páginas:
WOS Id: 001277321000001
ID de PubMed: 39065746
imagen gold, Green Published

MÉTRICAS